{"id":21568,"date":"2026-06-16T14:52:00","date_gmt":"2026-06-16T12:52:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=aab49da79d00059b4e4146314cfa0cb5"},"modified":"2026-06-16T14:52:00","modified_gmt":"2026-06-16T12:52:00","slug":"eurofins-scientific-director-pdmr-shareholding-4","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=21568","title":{"rendered":"Eurofins Scientific: Director\/PDMR Shareholding"},"content":{"rendered":"

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below.<\/p><\/a><\/a>

\nThis notification is made in accordance with the European Market Abuse Regulation.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p><\/td><\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n

\n1.<\/b><\/p><\/td>

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nName<\/p><\/td>

\nVIGNEAU Fran\u00e7ois<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n2.<\/b><\/p><\/td>

\nReason for the notification<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nPosition \/ status<\/p><\/td>

\nSenior Vice President<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nInitial notification \/ amendment<\/p><\/td>

\nInitial<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n3.<\/b><\/p><\/td>

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nName<\/p><\/td>

\nEurofins Scientific S.E.<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nLEI<\/p><\/td>

\n529900JEHFM47DYY3S57<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n4.<\/b><\/p><\/td>

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nDescription of the financial instrument, type of instrument<\/p><\/td>

\nShare<\/p><\/td><\/tr>\n

\nIdentification code<\/p><\/td>

\nISIN: FR0014000MR3<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nNature of the transaction<\/p><\/td>

\nExercise of stock options under the Eurofins stock option programme. Number of options exercised: 700<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\nTransaction is linked to the Eurofins stock option \/ free share \/ stock option program<\/p><\/td><\/tr>\n

\nc)<\/p><\/td>

\nPrice(s) and volume(s)<\/p><\/td>

\nPrice(s)<\/p><\/td>

\nVolume(s)<\/p><\/td><\/tr>\n

\nEUR 32.50<\/p><\/td>

\n100<\/p><\/td><\/tr>\n

\nd)<\/p><\/td>

\nAggregated information<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\n\u2014 Aggregated volume<\/p><\/td>

\n\n<\/tr>\n

\n\u2014 Price<\/p><\/td>

\nEUR 3,250.00<\/p><\/td><\/tr>\n

\ne)<\/p><\/td>

\nDate of the transaction<\/p><\/td>

\n2026-06-11<\/p><\/td><\/tr>\n

\nf)<\/p><\/td>

\nPlace of the transaction<\/p><\/td>

\nXPAR<\/p><\/td><\/tr>\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p><\/td><\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n

\n1.<\/b><\/p><\/td>

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nName<\/p><\/td>

\nVIGNEAU Fran\u00e7ois<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n2.<\/b><\/p><\/td>

\nReason for the notification<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nPosition \/ status<\/p><\/td>

\nSenior Vice President<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nInitial notification \/ amendment<\/p><\/td>

\nInitial<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n3.<\/b><\/p><\/td>

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nName<\/p><\/td>

\nEurofins Scientific S.E.<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nLEI<\/p><\/td>

\n529900JEHFM47DYY3S57<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\n<\/tr>\n

\n4.<\/b><\/p><\/td>

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p><\/td><\/tr>\n

\na)<\/p><\/td>

\nDescription of the financial instrument, type of instrument<\/p><\/td>

\nShare<\/p><\/td><\/tr>\n

\nIdentification code<\/p><\/td>

\nISIN: FR0014000MR3<\/p><\/td><\/tr>\n

\nb)<\/p><\/td>

\nNature of the transaction<\/p><\/td>

\nExercise of stock options under the Eurofins stock option programme. Number of options exercised: 700<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\nTransaction is linked to the Eurofins stock option \/ free share \/ stock option program<\/p><\/td><\/tr>\n

\nc)<\/p><\/td>

\nPrice(s) and volume(s)<\/p><\/td>

\nPrice(s)<\/p><\/td>

\nVolume(s)<\/p><\/td><\/tr>\n

\nEUR 32.50<\/p><\/td>

\n1400<\/p><\/td><\/tr>\n

\nd)<\/p><\/td>

\nAggregated information<\/p><\/td>

\n\u00a0<\/p><\/td><\/tr>\n

\n\u2014 Aggregated volume<\/p><\/td>

\n\n<\/tr>\n

\n\u2014 Price<\/p><\/td>

\nEUR 45,500.00<\/p><\/td><\/tr>\n

\ne)<\/p><\/td>

\nDate of the transaction<\/p><\/td>

\n2026-06-15<\/p><\/td><\/tr>\n

\nf)<\/p><\/td>

\nPlace of the transaction<\/p><\/td>

\nXPAR<\/p><\/td><\/tr>\n<\/table>

\nFor more information, please visit <\/b>www.eurofins.com<\/a><\/p>

\nAbout Eurofins \u2013 the global leader in bio-analysis\n<\/b>Eurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.\nEurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.<\/p> Contacts<\/b>

\nInvestor Relations\nEurofins Scientific SE\nPhone: +32 2 766 1620\nE-mail: ir@sc.eurofinseu.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below.
\nThis notificat…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-21568","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21568"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21568\/revisions"}],"predecessor-version":[{"id":21569,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21568\/revisions\/21569"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}